Lophos Holdings Inc

Lophos Holdings, Inc. engages in the research and development of compounds derived from peyote cactus. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2023-09-06. The firm is also engaged in the research and development of compounds derived from the peyote cactus. Its cultivated peyote cactus will be used by the Company to conduct pre-clinical research and development in Canada either directly through a Controlled Substance Dealers License (CSDL) at its Napanee facility, or indirectly with one or more third-party partners. Its CSDL licensing includes the development of intellectual property related to the chemical composition of peyote and the custom formulation of Mescaline and related compounds and the research and development of drug delivery systems for Mescaline and other related molecules. The company also operates a Health Canada licensed analytical testing and research and development institution, to conduct pre-clinical research and development.